SANGAMO THERAPEUTICS INC (SGMO)
US8006771062 - Common Stock
| MRQ (2024-9-30) | 2023 (2023-12-31) | 2022 (2022-12-31) | 2021 (2021-12-31) | 2020 (2020-12-31) | ||||
|---|---|---|---|---|---|---|---|---|
| ASSETS | ||||||||
| Current Assets | ||||||||
| Cash Equivalents | 39.20M | 45.20M | 100.40M | 178.90M | 131.30M | |||
| Marketable Securities | 0.00 | 35.80M | 177.20M | 197.70M | 510.10M | |||
| Receivables | 10.50M | 1.33M | 4.50M | 6.40M | 6.30M | |||
| Other Current Assets | 8.43M | 12.00M | 18.20M | 15.90M | 12.00M | |||
| Total Current Assets | 58.13M | 94.33M | 300.30M | 398.80M | 659.70M | |||
| Non-Current Assets | ||||||||
| PPE Net | 36.91M | 52.87M | 125.50M | 124.70M | 112.40M | |||
| Investments And Advances | N/A | 0.00 | 29.80M | 88.20M | 50.50M | |||
| Goodwill | N/A | 0.00 | 37.60M | 39.70M | 42.80M | |||
| Intangibles | N/A | 0.00 | 50.70M | 53.80M | 58.10M | |||
| Other Non-Current Assets | 16.22M | 18.13M | 18.50M | 16.80M | 15.10M | |||
| Total Non-Current Assets | 53.13M | 70.99M | 262.20M | 323.10M | 278.90M | |||
| TOTAL ASSETS | 111.26M | 165.32M | 562.50M | 721.90M | 938.60M | |||
| LIABILITIES | ||||||||
| Current Liabilities | ||||||||
| Short Term Debt | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | |||
| Accrued Expenses | 22.60M | 20.74M | 34.40M | 30.60M | 48.80M | |||
| Accounts Payable | 19.79M | 15.26M | 22.40M | 9.80M | -6.10M | |||
| Other Current Liabilities | 774.00K | 11.73M | 54.80M | 87.50M | 100.80M | |||
| Total Current Liabilities | 43.16M | 47.73M | 111.70M | 127.90M | 143.50M | |||
| Non-Current Liabilities | ||||||||
| Long Term Debt | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | |||
| Deferred Taxes/Income | N/A | 0.00 | 6.30M | 6.60M | 7.20M | |||
| Other Non-Current Liabilities | 28.97M | 34.70M | 149.60M | 212.00M | 290.50M | |||
| Total Non-Current Liabilities | 28.97M | 34.70M | 155.90M | 218.70M | 296.80M | |||
| TOTAL LIABILITIES | 72.13M | 82.43M | 267.60M | 346.60M | 440.30M | |||
| SHAREHOLDERS' EQUITY | ||||||||
| Retained Earnings | -1.48B | -1.41B | -1.15B | -956.30M | -778.00M | |||
| Additional Paid In Capital | 1.52B | 1.49B | 1.45B | 1.33B | 1.27B | |||
| Minority Interest | N/A | N/A | N/A | 0.00 | -900.00K | |||
| Common Shares | 2.09M | 1.78M | 1.70M | 1.50M | 1.40M | |||
| Other Shareholders' Equity | -4.22M | -4.59M | -8.40M | -4.00M | 5.40M | |||
| Shares Outstanding | 208.62M | 178.13M | 166.80M | 145.90M | 142.10M | |||
| Tangible Book Value per Share | 0.19 | 0.47 | 1.24 | 1.93 | 2.80 | |||
| Total Shareholders' Equity | 39.13M | 82.89M | 295.00M | 375.30M | 498.20M | |||
| TOTAL LIABILITIES AND EQUITY | 111.26M | 165.32M | 562.50M | 721.90M | 938.60M | |||
| Statistics | ||||||||
| Debt/Equity | N/A | N/A | N/A | N/A | N/A | |||
| Current Ratio | 1.35 | 1.98 | 2.69 | 3.12 | 4.60 | |||
| Return On Assets (ROA) | -165.31% | -155.96% | -34.19% | -24.70% | -12.89% | |||
| Return On Equity (ROE) | -470.00% | -311.06% | -65.19% | -47.51% | -24.29% | |||
All data in USD , ROIC based on taxRate of 0.21